Jack G. Schneider

Jack G. Schneider

Auto-generated profile, based on publicly available information

Jack G. Schneider

Division of Infectious Diseases, Departments of Medicine and Pediatrics, Indiana University School of Medicine and Riley Hospital for Children at Indiana University Health , Indianapolis, Indiana

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2023 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
MSMatthew Stack
Matthew Stack
JHJon Hiles
Jon Hiles
EVEthan Valinetz
Ethan Valinetz
SGSamir K Gupta
Samir K Gupta
SBSaira Butt
Saira Butt
JSJack G Schneider
Jack G Schneider
Cryptococcal meningitis is an uncommon but serious infection with high mortality and morbidity. Classically described in immunocompromised patients, including those with solid organ transplants or HIV/AIDS, cryptococcosis has also been reported in young and otherwise healthy patients, albeit rarely. We retrospectively searched for all cases of cryptococcal meningitis in young (≤50 years) and previously healthy patients with no known immunocompromising conditions from January 2015 to January 2022 at Indiana University Health (IU Health). Additionally, a PubMed literature review was performed with the keywords “cryptococcal meningitis” and “immunocompetent” from January 1988 to January 2022. Clinical courses, including outcomes and treatment regimens, were evaluated. We identified 4 local cases of cryptococcal meningitis in otherwise healthy patients age ≤50 years. Three cases were due to Cryptococcus neoformans, with 1 experiencing a postinfectious inflammatory response syndrome (PIIRS). The PubMed search identified 51 additional cases, with 32 (63%) being caused by Cryptococcus neoformans and 8 (17%) by Cryptococcus gattii. Of the 51 cases, only 2 resulted in death directly due to cryptococcosis. Fifteen (29%) had PIIRS, with steroid treatment documented in 11 of 15. Antifungal induction regimens and duration were varied but predominately consisted of amphotericin and flucytosine, with a mean induction duration of 5.0 weeks. Cryptococcal meningitis in young, previously healthy patients is likely under-recognized. PIIRS (akin to immune reconstitution inflammatory syndrome observed in HIV/AIDS) with prolonged recovery should be of concern. Determining risk factors for cryptococcosis in these patients remains elusive.

1 January 2019 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
PDF file
JSJack G Schneider
Jack G Schneider
JWJames B Wood
James B Wood
BSBryan H Schmitt
Bryan H Schmitt
CEChristopher L Emery
Christopher L Emery
TDThomas E Davis
Thomas E Davis
JMJohn J Manaloor
John J Manaloor
We evaluated the performance and time to result for pathogen identification (ID) and antimicrobial susceptibility testing (AST) of the Accelerate Pheno™ system (AXDX) compared with standard of care (SOC) methods. We also assessed the hypothetical improvement in antibiotic utilization if AXDX had been implemented. Clinical samples from patients with monomicrobial Gram-negative bacteraemia were tested and compared between AXDX and the SOC methods of the VERIGENE® and Bruker MALDI Biotyper® systems for ID and the VITEK® 2 system for AST. Additionally, charts were reviewed to calculate theoretical times to antibiotic de-escalation, escalation and active and optimal therapy ID mean time was 21 h for MALDI-TOF MS, 4.4 h for VERIGENE® and 3.7 h for AXDX. AST mean time was 35 h for VITEK® 2 and 9.0 h for AXDX. For ID, positive percentage agreement was 95.9% and negative percentage agreement was 99.9%. For AST, essential agreement was 94.5% and categorical agreement was 93.5%. If AXDX results had been available to inform patient care, 25% of patients could have been put on active therapy sooner, while 78% of patients who had therapy optimized during hospitalization could have had therapy optimized sooner. Additionally, AXDX could have reduced time to de-escalation (16 versus 31 h) and escalation (19 versus 31 h) compared with SOC. By providing fast and reliable ID and AST results, AXDX has the potential to improve antimicrobial utilization and enhance antimicrobial stewardship.

1 November 2019 in Diagnostic Microbiology and Infectious Disease
Verified
Journal Article
Closed access
JSJack G. Schneider
Jack G. Schneider
JWJames B. Wood
James B. Wood
NSNathan W. Smith
Nathan W. Smith
CEChristopher L. Emery
Christopher L. Emery
TDThomas E. Davis
Thomas E. Davis
BSBryan H. Schmitt
Bryan H. Schmitt

8 February 2024 in Journal of the Pediatric Infectious Diseases Society
Verified
Journal Article
Closed access
PDF file
JWJames B Wood
James B Wood
KRKelsey Russell
Kelsey Russell
TDTom E Davis
Tom E Davis
SPSarah Y Park
Sarah Y Park
MSMatthew J Smollin
Matthew J Smollin
JSJack G Schneider
Jack G Schneider
Background: Nearly half of all pediatric musculoskeletal infections (MSKIs) are culture negative. Plasma microbial cell-free DNA (mcfDNA) sequencing is noninvasive and not prone to the barriers of culture. We evaluated the performance of plasma mcfDNA sequencing in identifying a pathogen, and examined the duration of pathogen detection in children with MSKIs. Methods: We conducted a prospective study of children, aged 6 months to 18 years, hospitalized from July 2019 to May 2022 with MSKIs, in whom we obtained serial plasma mcfDNA sequencing samples and compared the results with cultures. Results: A pathogen was recovered by culture in 23 of 34 (68%) participants, and by initial mcfDNA sequencing in 25 of 31 (81%) participants. Multiple pathogens were detected in the majority (56%) of positive initial samples. Complete concordance with culture (all organisms accounted for by both methods) was 32%, partial concordance (at least one of the same organism(s) identified by both methods) was 36%, and discordance was 32%. mcfDNA sequencing was more likely to show concordance (complete or partial) if obtained prior to a surgical procedure (82%), compared with after (20%), (RR 4.12 [95% CI 1.25, 22.93], p = .02). There was no difference in concordance based on timing of antibiotics (presample antibiotics 60% vs no antibiotics 75%, RR 0.8 [95% CI 0.40, 1.46], p = .65]). mcfDNA sequencing was positive in 67% of culture-negative infections and detected a pathogen for a longer interval than blood culture (median 2 days [IQR 1, 6 days] vs 1 day [1, 1 day], p < .01). Conclusions: Plasma mcfDNA sequencing may be useful in culture-negative pediatric MSKIs if the sample is obtained prior to surgery. However, results must be interpreted in the appropriate clinical context as multiple pathogens are frequently detected supporting the need for diagnostic stewardship.

21 April 2023 in Pediatric Emergency Care
Verified
Journal Article
Closed access
SHSean M. Hanlon
Sean M. Hanlon
DSDon Sim
Don Sim
JSJack G. Schneider
Jack G. Schneider
ZYZiyi Yang
Ziyi Yang
STSean M. Thompson
Sean M. Thompson
Background/Objective: Throughout the pandemic, febrile seizures have resulted from infection secondary to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). The objective of this study is to determine if there is an increased association between COVID-19 and febrile seizures as compared with other causes of febrile seizures. Methods: This was a retrospective case control study. Data were collected from the National Institute of Health (NIH) supported National COVID Cohort Collaborative (N3C). Patients from 6 to 60 months who were tested for COVID-19 were included; cases were defined as COVID-19–positive patients whereas controls were defined as COVID-19–negative patients. Febrile seizures diagnosed within 48 hours of the COVID-19 test were considered to be associated with the test result. Patients were subjected to a stratified gender and date matching design followed by a logistic regression controlling for age and race. Results: During the study period, 27,692 patients were included. Of those, 6923 patients were COVID-19–positive, among which 189 had febrile seizures (2.7%). After logistic regression, the likelihood of having febrile seizures concurrently with COVID-19 as compared with other causes was 0.96 (P = 0.949; confidence interval, 0.81, 1.14). Conclusions: There were 2.7% of the patients with COVID-19 that were diagnosed with a febrile seizure. However, when subjected to a matched case control design with logistic regression controlling for confounding variables, there does not appear to be an increased risk of febrile seizures secondary to COVID-19 as compared with other causes.

14 June 2024 in Journal of the Pediatric Infectious Diseases Society
Verified
Journal Article
Closed access
PDF file
SHShannon Hamilton
Shannon Hamilton
MTMichael Taylor
Michael Taylor
JSJack G Schneider
Jack G Schneider
ZHZachary Howe
Zachary Howe
MSMeghna Sharma
Meghna Sharma
JWJames B Wood
James B Wood
Data are limited on the clinical impact of nasal methicillin-resistant Staphylococcus aureus (MRSA) polymerase chain reaction (PCR) testing (nMRSA-PCR) for orbital cellulitis. This two-center, retrospective study demonstrated a negative predictive value of 98.0% and an overall lower use of anti-MRSA antibiotics, without a concomitant increase in hospital readmission.